Home › Idiopathic Thrombocytopenic Purpura › New Jersey
Idiopathic Thrombocytopenic Purpura clinical trials in New Jersey
4 studies for Idiopathic Thrombocytopenic Purpura are looking for participants at sites in New Jersey.
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
- Astera Cancer Center, East Brunswick
- Summit Medical Group, Summit
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07421167A Study of Patients' Preferences for Primary Immune Thrombocytopenia Treatment
- Novartis, East Hanover
RecruitingObservational study
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07786077A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- American Oncology Partners of Maryland, PA, Morristown
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06948318A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
- Regional Cancer Care Associates, LLC (RCCA), Little Silver
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 1, 2026 · NCT06544499From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.